Congressos e publicações

Adverse events of interest with zanubrutinib vs fixed-duration combination of venetoclax + obinutuzumab in treatment-naive chronic lymphocytic leukemia A network meta-analysis (NMA) of efficacy of zanubrutinib versus fixed-duration acalabrutinib plus venetoclax in treatment-naïve (TN) chronic lymphocytic leukemia (CLL) A qualitative study to explore the patient experience of continuous covalent bruton tyrosine kinase (BTK) inhibitors in chronic lymphocytic leukemia (CLL): study methodology AdvanTIG-101: a Phase 1b/2 study of ociperlimab (anti-TIGIT) plus tislelizumab (anti-PD-1) or rituximab in relapsed/refractory diffuse large b-cell lymphoma BGB-11417-302, a Phase 3, randomized, double-blind study of sonrotoclax (BGB-11417) + zanubrutinib vs placebo + zanubrutinib in patients with relapsed or refractory mantle cell lymphoma Combination of zanubrutinib + venetoclax for treatment-naive CLL/SLL: results in SEQUOIA arm D Combination treatment with novel BCL2 inhibitor sonrotoclax (BGB-11417) and zanubrutinib induces high rate of complete remission for patients with relapsed/refractory mantle cell lymphoma Comparative Efficacy of Zanubrutinib versus Fixed-Duration Acalabrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL): A Matching-Adjusted Indirect Comparison (MAIC) Efficacy of continuous zanubrutinib vs fixed-duration venetoclax in combination with obinutuzumab in treatment-naive chronic lymphocytic leukemia: a matching-adjusted indirect comparison Evaluating uptake of targeted agents by race/ethnicity in patients receiving first-line treatment for chronic lymphocytic leukemia Final analysis of a Phase 1 study of zanubrutinib (Zanu) plus lenalidomide (Len) in patients with relapsed/refractory (R/R) diffuse large b-cell lymphoma (DLBCL) Final independent review data supports sustained benefit of zanubrutinib over ibrutinib in patients with R/R CLL/SLL in ALPINE Preferences for treatment in first-line chronic lymphocytic leukemia: a multi-criteria decision analysis in Italy Primary analysis results of novel bcl2 inhibitor sonrotoclax (BGB-11417) monotherapy in patients with relapsed/refractory b-cell malignancies Real-World Zanubrutinib Treatment Paterns in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Among US Community Oncology Patients With Prior Acalabrutinib Therapy Real-World bruton tyrosine kinase inhibitor use and clinical outcomes among patients with chronic lymphocytic leukemia/small lymphocytic lymphoma Real-World comparative effectiveness of first-line bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukemia Real-World treatment utilization patterns, discontinuation and healthcare resource utilization of first-line Bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia: age-related disparity Real-World zanubrutinib treatment paterns in mantle cell lymphoma among US community oncology patients with prior bruton tyrosine kinase inhibitor therapy Real-world burden of disease, treatment paterns and outcomes in patients with mantle cell lymphoma (MCL) Risk of hypertension in patients newly diagnosed with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and treated with covalent bruton tyrosine kinase inhibitors (cBTKi): A Real-World study SEQUOIA 5-year follow-up in arm C: frontline zanubrutinib monotherapy in patients with del(17p) and treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) Serious infections in patients with CLL/SLL treated with combination venetoclax and obinutuzumab compared with those treated with zanubrutinib: a real-world study Sonrotoclax monotherapy for treatment of patients with relapsed/refractory CLL: data from an ongoing Phase 1/1B study (BGB-11417-101) Updated efficacy & safety of the bruton tyrosine kinase (btk) degrader BGB-16673 in patients with relapsed/refractory waldenström macroglobulinemia (WM): ongoing phase (PH) 1 CADANCE-101 study results Updated efficacy and safety of the bruton tyrosine kinase (BTK) degrader BGB-16673 in patients (PTS) with relapsed or refractory (R/R) CLL/SLL: results from the ongoing Phase (PH) 1 CADANCE-101 study Updated interim results of sonrotoclax + dexamethasone in patients with t(11;14)-positive relapsed/refractory multiple myeloma: an all-oral treatment Updated results from the Phase 1 study of sonrotoclax (bgb-11417), a novel BCL2 inhibitor, in combination with zanubrutinib for relapsed/refractory CLL/SLL demonstrate deep and durable responses Updated safety & antileukemic activity data of sonrotoclax (BGB-11417), a potent and selective BCL2 inhibitor, in treatment-naive patients with acute myeloid leukemia unfit for intensive chemotherapy Updated safety and antileukemic activity data for sonrotoclax (BGB-11417), a potent and selective bcl2 inhibitor, in patients with relapsed/refractory acute myeloid leukemia Updated safety and efficacy results of a Phase 1 study of the novel BCL2 inhibitor sonrotoclax (BGB-11417) for relapsed/refractory waldenström macroglobulinemia

Combination of zanubrutinib and venetoclax for treatment-naive CLL/SLL: results in SEQUOIA Arm D SEQUOIA 5-year follow-up in Arm C: frontline zanubrutinib monotherapy in patients with del(17p) and treatment-naive CLL/SLL

Final analysis of a multicenter, open-label, Phase 2 study evaluating the efficacy and safety of tislelizumab (TIS) in combination with fruquintinib (F) in patients with selected solid tumors Lung cancer enrollment of demographic subgroups in US clinical trial sites Treatment preferences of patients, caregivers, and physicians in follicular lymphoma: A global discrete-choice experiment study

A first-in-human, phase 1a/b, dose-escalation/expansion study of BG-68501, a selective CDK2 inhibitor, as monotherapy or in combination with fulvestrant for patients with HR+/HER2- breast cancer and other advanced solid tumors: first disclosure of clinical data A network meta-analysis (NMA) of efficacy of zanubrutinib versus fixed-duration acalabrutinib plus venetoclax in treatment-naïve chronic lymphocytic leukemia (CLL) A phase 1 study of the OX40 agonist, BGB-A445, with or without tislelizumab, an anti-PD-1 monoclonal antibody, in patients with advanced NSCLC, HNSCC or NPC A phase 2 study of the OX40 agonist BGB-A445, in combination with docetaxel or BGB-15025, an HPK1 inhibitor, in patients with NSCLC pretreated by anti-PD-(L)1 antibodies Adverse events of interest (AEIs) with zanubrutinib vs fixed-duration combination of venetoclax + obinutuzumab in treatment-naïve chronic lymphocytic leukemia (CLL) Combination of zanubrutinib and venetoclax for treatment-naïve CLL/SLL: results in SEQUOIA arm D Comparative efficacy of zanubrutinib versus fixed-duration acalabrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia (CLL): a matching-adjusted indirect comparison (MAIC) Comparing real-world treatment patterns and outcomes of zanubrutinib and acalabrutinib in CLL/SLL at University of California academic health centers Efficacy of continuous zanubrutinib vs fixed-duration venetoclax in combination with obinutuzumab in treatment-naïve chronic lymphocytic leukemia (CLL): a matching-adjusted indirect comparison (MAIC) Evaluating uptake of targeted agents by race/ethnicity in patients receiving first-line treatment for chronic lymphocytic leukemia (CLL) Final analysis of a multicenter, open-label, phase 2 study evaluating the efficacy and safety of tislelizumab in combination with fruquintinib in patients with selected solid tumors First-in-human study of BG-C9074: Preliminary results of the dose-escalation phase Lung cancer enrollment of demographic subgroups in US clinical trial sites Real-world Bruton tyrosine kinase inhibitor (BTKi) use and clinical outcomes among patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) Real-world comparative effectiveness of first-line Bruton tyrosine kinase inhibitors (BTKis) in patients with chronic lymphocytic leukemia Real-world treatment utilization patterns, discontinuation and healthcare resource utilization of first-line Bruton tyrosine kinase inhibitor (BTKi) in chronic lymphocytic leukemia (CLL): age-related disparity Real-world zanubrutinib treatment patterns in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) among US community oncology patients with prior acalabrutinib therapy Real-world zanubrutinib treatment patterns in mantle cell lymphoma (MCL) among US community oncology patients with prior Bruton tyrosine kinase inhibitor (BTKi) therapy Risk of hypertension in patients newly diagnosed with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and treated with covalent Bruton tyrosine kinase inhibitors (cBTKi): a real-world study SEQUOIA 5-year follow-up in arm C: frontline zanubrutinib monotherapy in patients with del(17p) and treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma Serious infections in patients with CLL/SLL treated with combination venetoclax and obinutuzumab compared with those treated with zanubrutinib: a real-world study Tislelizumab plus chemotherapy/chemoradiotherapy as positron emission tomography (PET)-guided neoadjuvant treatment for resectable esophageal squamous cell carcinoma (R-ESCC): RATIONALE-213 final analysis Treatment preferences of patients, caregivers, and physicians in follicular lymphoma (FL): a global-discrete experience (DCE) study

Examining the impact of tislelizumab added to chemotherapy on health‑related quality of life (HRQoL) outcomes in patients with extensive-stage small cell lung cancer (ES-SCLC) Recurrent patient-reported outcome (PRO)-based symptomatic deterioration predicts survival and disease progression in patients with resectable non-small cell lung cancer (NSCLC): post-hoc analysis of RATIONALE-315 Systematic literature review (SLR) of disease burden related to first-line (1L) unresectable, locally advanced, or metastatic gastric cancer (GC) and gastroesophageal junction (GEJ) adenocarcinoma Systematic literature review (SLR) of disease burden related to first-line (1L) unresectable, locally advanced, or metastatic gastric cancer (GC) and gastroesophageal junction (GEJ) adenocarcinoma (supplement)

Examining the impact of tislelizumab added to chemotherapy on health‑related quality of life (HRQoL) outcomes in patients with extensive-stage small cell lung cancer (ES-SCLC) Recurrent patient-reported outcome (PRO)-based symptomatic deterioration predicts survival and disease progression in patients with resectable non-small cell lung cancer (NSCLC): Post-hoc analysis of RATIONALE-315 Systematic literature review (SLR) of disease burden related to first-line (1L) unresectable, locally advanced, or metastatic gastric cancer (GC) and gastroesophageal junction (GEJ) adenocarcinoma

BGB-16673, a BTK degrader, in patients with R/R CLL/SLL: Preliminary phase 1 results from CaDAnCe-101

Extended follow-up of zanubrutinib-treated patients with Waldenström macroglobulinemia from the ASPEN trial through LTE1 Proposed standard of care for active monitoring in Waldenström macroglobulinemia from a UK-wide patient-expert collaboration Sonrotoclax + zanubrutinib for TN-CLL demonstrates MRD clearance and tolerability in ongoing phase 1/1b (BGB-11417-101)

BGB-16673, a BTK degrader, in patients with R/R CLL/SLL: Preliminary phase 1 results from CaDAnCe-101 Extended follow-up of zanubrutinib-treated patients with Waldenström macroglobulinemia from the ASPEN trial through LTE1 Proposed standard of care for active monitoring in Waldenström macroglobulinemia from a UK-wide patient-expert collaboration Sonrotoclax + zanubrutinib for TN-CLL demonstrates MRD clearance and tolerability in ongoing phase 1/1b (BGB-11417-101)

Preclinical evaluation of BG-C137, a potential first-in-class FGFR2b targeting ADC, for the treatment of FGFR2b-expressing cancer

Anti-CCR8 mediates long-lasting antitumor immunological memory and enhances anti-tumor immunity in immune-cold cancer through the combination with chemotherapy BG-C477, a novel topoisomerase 1 inhibitor-based ADC, exhibits antitumor activity in carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5)-expressing preclinical models BGB-A3055, an afucosylated anti-CCR8 antibody, preferentially depletes intratumoral regulatory T cells and inhibits tumor growth in preclinical models BGB-B2033, a novel 4-1BB/GPC3 bispecific antibody, exhibits potent in vitro and in vivo antitumor activity in preclinical models BGB-C354, a novel B7H3 ADC with high DAR stability and strong bystander effect, demonstrates robust antitumor activity in preclinical models BGB-R046, an IL-15 pro-drug demonstrates robust pharmacodynamic effects and immune activation within tumor microenvironment in a mouse syngeneic model BTK T474I with enhanced kinase activity confers growth advantage over BTK-L528W with kinase deficiency in B malignant cells Deep plasma proteome profiling to discover drug treatment related novel biomarkers in non-small cell lung cancer EGFR x MET TsAb: differentiated MET biparatopic design with optimal MET inhibitory activity to pursue best-in-class opportunity Integrative spatial and single-cell analysis elucidates tumor microenvironment heterogeneity in NSCLC Preclinical characterization of BGB-B3227, a MUC1 x CD16A bispecific engager, for the treatment of MUC1-expressing solid tumor Preclinical evaluation of BG-C137, a potential first-in-class FGFR2b targeting ADC, for the treatment of FGFR2b-expressing cancer Single-cell gene expression profiling of the tumor immune microenvironment (TIME) and its association with immunotherapy response in syngeneic mouse models Zanubrutinib (zanu) overcomes BTK-V416L resistance in B cell lymphoma models iPSC-derived γδT with novel combinatorial knockout demonstrated significant anti-tumor activity and extended longevity without cytokine support

A first-in-human phase 1a/b study of BGB-58067, an MTA-cooperative PRMT5 inhibitor, in patients with advanced solid tumors and MTAP deficiency Anti-CCR8 mediates long-lasting antitumor immunological memory and enhances anti-tumor immunity in immune-cold cancer through the combination with chemotherapy BG-C477, a novel topoisomerase 1 inhibitor-based ADC, exhibits antitumor activity in carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5)-expressing preclinical models BGB-B2033, a novel 4-1BB/GPC3 bispecific antibody, exhibits potent in vitro and vivo antitumor activity in preclinical model BGB-C354, a novel B7H3 ADC with high DAR stability and strong bystander effect, demonstrates robust antitumor activity in preclinical models BGB-R046, an IL-15 pro-drug demonstrates robust pharmacodynamic effects and immune activation within tumor microenvironment in a mouse syngeneic model BGBA3055, an afucosylated anti-CCR8 antibody, preferentially depletes intratumoral regulatory T cells and inhibits tumor growth in preclinical models BTK T474I with enhanced kinase activity confers growth advantage over BTK-L528W with kinase deficiency in B malignant cells Deep plasma proteome profiling to discover drug treatment related novel biomarkers in non-small cell lung cancer EGFR x MET tsAb: differentiated MET biparatopic design with optimal MET inhibitory activity to pursue best-in-class opportunity Integrative spatial and single-cell analysis elucidates tumor microenvironment heterogeneity in NSCLC Preclinical characterization of BGB-B3227, a MUC1 x CD16A bispecific engager, for the treatment of MUC1-expressing solid tumors: Preclinical evaluation of BG-C137, a potential first-in-class FGFR2b targeting ADC, for the treatment of FGFR2b-expressing cancer Single-cell gene expression profiling of the tumor immune microenvironment (TIME) and its association with immunotherapy response in syngeneic mouse models Zanubrutinib (zanu) overcomes BTK V416L resistance in B cell lymphoma models iPSC-derived gdT with novel combinatorial KO demonstrated significant anti-tumor activity and extended longevity without cytokine support

L’association sonrotoclax et zanubrutinib permet des taux élevés de clairance de la maladie résiduelle avec une tolérance satisfaisante en première ligne de leucémie lymphoïde chronique : données de l’étude de phase 1/1b en cours BGB-11417-101 Sonrotoclax and zanubrutinib as frontline treatment for CLL demonstrates high MRD clearance rates with good tolerability: data from an ongoing phase 1/1b study BGB-11417-101

Analyse comparative d’efficacité de zanubrutinib plus obinutuzumab dans le lymphome folliculaire en rechute/réfractaire : Growth Modulation Index (GMI) dans l'étude ROSEWOOD Comparative efficacy of zanubrutinib plus obinutuzumab versus last prior treatment in relapsed/refractory follicular lymphoma: Growth modulation index analysis from ROSEWOOD study Le zanubrutinib a démontré une tolérance et une efficacité chez les patients intolérants à l’acalabrutinib traités pour des néoplasies lymphoïdes B Preliminary efficacy and safety of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed or refractory Waldenström macroglobulinemia: results from the phase 1 CaDAnCe-101 study Preliminary efficacy and safety of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma: results from the phase 1 CaDAnCe-101 study Résultats d’efficacité et de tolérance du dégradeur de la tyrosine kinase de Bruton BGB-16673 chez les patients atteints de leucémie lymphoïde chronique/lymphome lymphocytique en rechute et/ou réfractaire : résultats de l’étude de phase 1 CaDAnCe-101 Résultats préliminaires d’efficacité et de tolérance du dégradeur de la tyrosine kinase de Bruton (BTK) BGB-16673 chez les patients atteints de macroglobulinémie de Waldenström (MW) en rechute ou réfractaire : résultats de l’étude de phase 1 CaDAnCe-101 Utilisation des inhibiteurs de tyrosine kinase de Bruton (iBTK) en vie réelle et résultats cliniques chez les patients atteints d’une leucémie lymphoïde chronique (LLC) ou d’un lymphome lymphocytique (LL) Zanubrutinib is well tolerated and effective in acalabrutinib-intolerant patients with B-cell malignancies

Analyse comparative d’efficacité de zanubrutinib plus obinutuzumab dans le lymphome folliculaire en rechute/réfractaire : Growth Modulation Index (GMI) dans l'étude ROSEWOOD Comparative efficacy of zanubrutinib plus obinutuzumab versus last prior treatment in relapsed/refractory follicular lymphoma: Growth modulation index analysis from ROSEWOOD study Le zanubrutinib a démontré une tolérance et une efficacité chez les patients intolérants à l’acalabrutinib traités pour des néoplasies lymphoïdes B L’association sonrotoclax et zanubrutinib permet des taux élevés de clairance de la maladie résiduelle avec une tolérance satisfaisante en première ligne de leucémie lymphoïde chronique : données de l’étude de phase 1/1b en cours BGB-11417-101 Preliminary efficacy and safety of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed or refractory Waldenström macroglobulinemia: results from the phase 1 CaDAnCe-101 study Preliminary efficacy and safety of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma: results from the phase 1 CaDAnCe-101 study Real-world Bruton tyrosine kinase inhibitor treatment patterns and outcomes among patients with CLL/SLL in US community oncology practices Résultats d’efficacité et de tolérance du dégradeur de la tyrosine kinase de Bruton BGB-16673 chez les patients atteints de leucémie lymphoïde chronique/lymphome lymphocytique en rechute et/ou réfractaire : résultats de l’étude de phase 1 CaDAnCe-101 Résultats préliminaires d’efficacité et de tolérance du dégradeur de la tyrosine kinase de Bruton (BTK) BGB-16673 chez les patients atteints de macroglobulinémie de Waldenström (MW) en rechute ou réfractaire : résultats de l’étude de phase 1 CaDAnCe-101 Sonrotoclax and zanubrutinib as frontline treatment for CLL demonstrates high MRD clearance rates with good tolerability: data from an ongoing phase 1/1b study BGB-11417-101 Utilisation des inhibiteurs de tyrosine kinase de Bruton (iBTK) en vie réelle et résultats cliniques chez les patients atteints d’une leucémie lymphoïde chronique (LLC) ou d’un lymphome lymphocytique (LL) Zanubrutinib is well tolerated and effective in acalabrutinib-intolerant patients with B-cell malignancies